Loading...
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy : Analysis of the EMPHASIS-HF study
Krum, Henry Shi, Harry Pitt, Bertram McMurray, John Swedberg, Karl van Veldhuisen, Dirk J. Vincent, John Pocock, Stuart J. Zannad, Faiez
Krum, Henry
Shi, Harry
Pitt, Bertram
McMurray, John
Swedberg, Karl
van Veldhuisen, Dirk J.
Vincent, John
Pocock, Stuart J.
Zannad, Faiez
Abstract
In EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure), eplerenone significantly reduced major cardiovascular events versus placebo in 2737 patients with mild symptoms of heart failure and an ejection fraction of <35%, in addition to recommended therapy. However, it is not known whether such benefits were preserved in patients receiving optimal background drug therapy, that is, high doses of angiotensin-converting enzyme inhibitor (ACEi, or angiotensin receptor blocker), β-blocker, or both drug classes.
Keywords
ACE inhibitor, aldosterone, angiotensin receptor blocker, β-blocker, eplerenone, heart failure
Date
2013
Type
Journal article
Journal
Circulation: Heart Failure
Book
Volume
6
Issue
4
Page Range
711-718
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
Open access
License
File Access
Controlled